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Background-—Guanylyl cyclase, a heme-containing a1b1 heterodimer (GC1), produces cGMP in response to Nitric oxide (NO)
stimulation. The NO-GC1-cGMP pathway negatively regulates cardiomyocyte contractility and protects against cardiac
hypertrophy–related remodeling. We recently reported that the b1 subunit of GC1 is detected at the intercalated disc with
connexin 43 (Cx43). Cx43 forms gap junctions (GJs) at the intercalated disc that are responsible for electrical propagation. We
sought to determine whether there is a functional association between GC1 and Cx43 and its role in cardiac homeostasis.
Methods and Results-—GC1 and Cx43 immunostaining at the intercalated disc and coimmunoprecipitation from membrane
fraction indicate that GC1 and Cx43 are associated. Mice lacking the a subunit of GC1 (GCa1 knockout mice) displayed a
signiﬁcant decrease in GJ function (dye-spread assay) and Cx43 membrane lateralization. In a cardiac-hypertrophic model,
angiotensin II treatment disrupted the GC1-Cx43 association and induced signiﬁcant Cx43 membrane lateralization, which was
exacerbated in GCa1 knockout mice. Cx43 lateralization correlated with decreased Cx43-containing GJs at the intercalated disc,
predictors of electrical dysfunction. Accordingly, an ECG revealed that angiotensin II–treated GCa1 knockout mice had impaired
ventricular electrical propagation. The phosphorylation level of Cx43 at serine 365, a protein-kinase A upregulated site involved in
trafﬁcking/assembly of GJs, was decreased in these models.
Conclusions-—GC1 modulates ventricular Cx43 location, hence GJ function, and partially protects from electrical dysfunction in an
angiotensin II hypertrophy model. Disruption of the NO-cGMP pathway is associated with cardiac electrical disturbance and
abnormal Cx43 phosphorylation. This previously unknown NO/Cx43 signaling could be a protective mechanism against stress-
induced arrhythmia. ( J Am Heart Assoc. 2017;6:e006397. DOI: 10.1161/JAHA.117.006397.)
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T he NO sensor, guanylyl cyclase (GC1), is a heterodimericenzyme that produces the second messenger cGMP.
Binding of NO to the heme of GC1 increases the catalytic
activity >50-fold. The NO-GC1-cGMP pathway regulates
numerous cardiovascular functions, including vascular tone
and cardiac homeostasis, mostly through activation of protein
kinase G. Speciﬁcally in the heart, the NO-cGMP signaling has
a well-established cardioprotective effect against hypertrophy,
acute ischemia/reperfusion injury, and heart failure.1 In
isolated cardiomyocytes from systemic GCa1 knockout
(GCa1-KO) mice, a model used herein, it was shown that
GC1 modulates cardiac contractility by mediating both neg-
ative and positive ionotropic effects, under b3 adrenergic
stimulation and basal condition, respectively.2 Other speciﬁc
cardiac roles for the pathway are not as well understood or
remain controversial, mostly because disruption or stimulation
of the NO-cGMP pathway affects many cell types in the heart.3
In most cell types, GC1 is found in the cytosol, but in
cardiomyocytes, it is also found at the plasma membrane (PM)
and is active.4,5 Moreover, in a model of cardiac hypertrophy
induced by pressure overload, the GCb1 subunit was shown
to redistribute from the caveolin 3–enriched microdomain at
the PM to the cytosol with a concomitant decrease in
NO-stimulated activity.6 We recently reported the detection of
neuronal NO synthase and the GCb1 subunit at the interca-
lated disc (ID),7 which could suggest that a functional
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NO-cGMP pathway is present at the ID, the site of the
mechanical and electrical conduction between cardiomy-
ocytes. Electrical coupling depends on connexin 43 (Cx43)–
containing gap junctions (GJs).8 Formation of Cx43-containing
GJs at the ID involves trafﬁcking from the endoplasmic
reticulum to the Golgi and the PM, then assembly and
stabilization in the ID structure.9 Each step of this cycle is
controlled by a complex, not fully understood sequence of
kinase activation that leads to Cx43 phosphorylation events
and by interaction with several additional binding partners.
The cAMP-activated protein kinase A (PKA) is proposed to be
involved in the Cx43-GJ assembly step.10,11
In cardiomyocytes, the activity of phosphodiesterases
allows the compartmentalization of cyclic nucleotide signal-
ing.12 In speciﬁc microdomains, cGMP can modulate cAMP
signaling by activation or inhibition of cAMP breakdown by
phosphodiesterases 2 and 3, respectively. The organization in
microdomains and the cAMP/cGMP interplay are areas under
intense investigation because disruption of the cAMP/cGMP
spatiotemporal distribution is associated with cardiac dys-
function.13,14 Our initial observation that GC1 was located at
the ID and the novel ﬁnding of its proximity to Cx43 prompted
us to investigate the potential function of the NO-cGMP
pathway in relation to Cx43 function. In addition to the GCa1-
KO mouse model, we used an angiotensin II (AngII)–induced
cardiac hypertrophy mouse model because AngII-treated
animals have decreased NO-stimulated GC1 activity in the
cardiovascular system.15 In our speciﬁc model, we observed
cardiac hypertrophy, but the cardiac remodeling associated
with arrhythmic sudden death and heart failure has not yet
taken place, unlike other renin-angiotensin mouse models.16,17
We describe herein the exploration of the GC1 cardiac role,
its association with Cx43, and its involvement in regulating
cardiac rhythm under basal and stress conditions.
Methods
Materials
The following reagents were purchased or otherwise obtained:
AngII (Sigma); miniosmotic pump (Alzet, Cupertino, CA; model
2002); Tissue-Tek O.C.T compound (Sakura; Finetek; Torrance,
CA);M.O.M (Mouse onMouseDetection kit; Vector Laboratory);
protease inhibitor cocktail (Sigma); protein A magnetic beads
(Dynabeads protein A; Thermo Fisher Scientiﬁc); Laemmli
Sample Buffer (Bio Rad); glass slides (Superfrost; VWR); Amicon
Ultra-0.5 centrifugation ﬁlter devices (Millipore); anti-GCa1
(rabbit; Sigma); anti-GCb1 (rabbit; Cayman); anti-Cx43 against
the C-terminus of Cx43 (mouse; Sigma) and against the
N-terminus of Cx43 (rabbit; Abcam); phosphospeciﬁc antibody
against serine 365 of Cx43 (from Dr P. Lampe; Iowa city, IA.);
anti–N-cadherin (rat; DSHB; Iowa city, IA.); anti–b-actin (mouse;
DSHB); rabbit IgG (Alpha Diagnostic Intl Inc; San Antonio, TX.);
antibodies AlexaFluor (488/594) goat anti-mouse, anti-rabbit,
and anti-rat, wheat germ agglutinin AlexaFluor647, and Prolong
antifade reagent with 40,6-diamidino-2-phenylindole (all from
Thermo Fisher Scientiﬁc).
Animals
The use of 3.5- to 6-month-old male mice in the study
conformed to standards in the Guide for the Care and Use of
Laboratory Animals, published by the US National Institutes of
Health, and was approved by the IACUC of Rutgers University.
Wild-type (WT; C57Bl6) mice were purchased from Jackson
Laboratory (Bar Harbor, ME) and housed in our animal facility.
GCa1-KO18 were backcrossed for >15 generations in a
C57Bl6 background, bred, and housed in our facility. Animals
were kept in a 12-hour light/dark cycle, and food and water
were given ad libitum.
AngII Treatment
Mice were treated with AngII (0.8 mg/kg per day) for 13 days
via miniosmotic pump implanted subcutaneously on animals
anesthetized with rodent cocktail (90 mg/kg ketamine+10
mg/kg xylazine, IP), as previously described.15 Buprenorphine
hydrochloride (0.03 mg/kg, SC) was administered as an
analgesic after surgery. Thirteen days after pump implanta-
tion, mice were anesthetized and their hearts were removed,
washed in PBS, and processed accordingly for each protocol.
Clinical Perspective
What Is New?
• The interaction between NO signaling through guanylyl
cyclase and connexin 43 modulates cardiac electrical
function.
• The NO–guanylyl cyclase–cGMP pathway is involved in
proper connexin 43 location and gap junction function at
the intercalated disc.
• Disruption of guanylyl cyclase signaling is associated with
connexin 43 lateralization, abnormal phosphorylation, and
stress-induced ventricular electrical defects.
What Are the Clinical Implications?
• Interactions between connexin 43 and NO–guanylyl cyclase
signaling may be disrupted under pathological conditions,
such as renin-angiotensin system hyperactivation, poten-
tially leading to arrhythmia.
• Pharmacological increases of cardiac cGMP at the interca-
lated disc might be able to correct or prevent cardiac
electrical defects.
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The apex of hearts was embedded in Tissue-Tek and progres-
sively frozen to 50°C before storage at 80°C. Transversal
cryosections (7–10 µm thick) were mounted onto glass slides
and processed, as described.7 Brieﬂy, cryosections were
incubated with appropriate primary and ﬂuorescent secondary
antibodies (GCa1, 1:1000; GCb1, 1:200; Cx43, 1:200; N-
cadherin, 1:100; secondary antibodies, 1:200) diluted in
M.O.M blocking reagent. Membranes were stained with wheat
germ agglutinin, and slides were covered with a glass coverslip
with antifade reagent. Fluorescence signals were imaged using
a 200 Axiovert ﬂuorescence microscope (Zeiss, Germany)
equipped with 910, 920, 940, and an oil 963 objectives and
a confocal-like system (ApoTome; Zeiss), with sections imaged
every 0.5 to 0.7 µm. 3-Dimensional reconstitution and optical
sectioning were done with Zeiss Axovision software. Fluores-
cence was standardized across conditions. A960 oil objective
was used to obtain pictures of Figure 1B. For quantiﬁcation of
Cx43 immunoﬂuorescence signal outside of the ID, 3 to 5
images per heart (4–5 animals per group from 4 independent
experiments) were used. For each experiment, the same
exposure times were used for imaging and, using ImageJ
software, the digitized images were corrected with the same
threshold for analysis of Cx43 and N-cadherin signals (pixels).
For each frame, the totality of Cx43 signal area was measured,
as was N-cadherin signal area (speciﬁc marker of the ID). The
total area of Cx43 overlapping with N-cadherin signal was
subtracted to obtain the area of Cx43 outside of the ID (pixels
unit). The percentage was determined by the ratio of Cx43 area
outside the ID/total Cx43 signal area.
Fractionation
Mouse hearts were washed in PBS and ground with an Ultra-
Turrax dispenser (IKA, Wilmington, NC.) in cold lysis buffer
without Triton X-100 (50 mmol/L Tris HCl, pH 7.5, 150 mmol/
L NaCl, 1 mmol/L EGTA, 1 mmol/L EDTA, 50 mmol/L NaF,
1 mmol/L Na orthovanadate, and protease inhibitor cocktail).
Lysate was centrifuged (4°C, 2 minutes, 500g) to remove
debris. Lysate without debris was centrifuged for 10 minutes at
21 000g at 4°C, and the supernatant (cytosolic fraction) was
collected. Pellet (total membrane) was washed and resus-
pended in lysis buffer containing 1% Triton, X-100 then
centrifuged at 9400g for 5 minutes at 4°C. Supernatant
(Triton-soluble membranes, including nonjunctional Cx43)
was collected, and the pellet (junctional plaques/ID fraction)
was dissolved in lysis buffer containing 1% Triton X-100 and
4 mol/L urea and then desalted with an Amicon ﬁlter (as done
by Bruce et al,19 with modiﬁcations). The 3 fractions (cytosolic,
Triton-soluble membrane, and junctional plaques) were solubi-
lized in Laemmli buffer, separated by SDS-PAGE on 7.5%
acrylamide gel, and processed for Western blot analysis.
Immunoprecipitation
Harvested hearts were homogenized in 2 to 3 mL of cold lysis
buffer with Triton X-100 (described previously) and centrifuged
at 3400g, 4°C, for 2 minutes to remove debris. Protein of the
supernatant (1 mg) in 1.5 mL of lysis buffer was precleared
with rabbit IgG antibodies bound to protein A. Precleared
samples were incubated overnight at 4°C with 3 lg of
antibodies anti-GCb1 or with 3 lg of rabbit IgG antibodies
as a negative control. Samples were rotated for 1 hour at room
temperature in the presence of protein A beads. Supernatant
was collected (unbound fraction), and immunoprecipitated
proteins were eluted at 90°C for 5 minutes in 19 ﬁnal
Laemmli sample buffer with 5% b-mercaptoethanol and
processed for Western blot analysis, as described above.
Dye Spread Assay
A modiﬁed protocol from Sovari et al17 was used to evaluate
GJ function in WT and GCa1-KO mice hearts. Hearts were
harvested and washed in PBS, as described previously. The
apex and top sliced part of ventricles were placed in PBS at
37°C, and a 27-gauge needle was used to infuse droplets of
0.5% Lucifer Yellow (LY; Thermo Fisher Scientiﬁc, Waltham,
MA.) and 0.5% Texas Red Dextran (molecular weight, 10 000;
Thermo Fisher Scientiﬁc) prepared in 150 mmol/L LiCl
solution. After 15 minutes of incubation, the samples were
ﬁxed in 4% formaldehyde for 30 minutes, washed in PBS, and
cryofrozen. Cryosections (14-µm thick) were mounted onto
microscope slides and examined using a 200 Axiovert Zeiss
microscope, 910 objective. The ﬁlters were set at Excita-
tion470/Emission509 for LY and Excitation540/Emission580
for Texas Red Dextran. The area of distribution of LY
ﬂuorescence and the area of distribution of Texas Red
Dextran ﬂuorescence were quantiﬁed with Axiovision soft-
ware. A total of 3 to 7 areas were imaged and analyzed for
each heart from 5 WT and 5 GCa1-KO mice (3 months old).
The difference between LY spread area and Texas Red
Dextran spread area was calculated to determine GJ perme-
ability. LY acts as a “tracer” for diffusion through GJ, but the
molecules of Texas Red Dextran are too large to go through GJ
and will stain cardiomyocytes at the site of injection.
Electrocardiography
Mouse ECGs were recorded using needle electrodes in a lead II
conﬁguration on mice anesthetized with 2,2,2-tribromoethanol
(Avertin; 290 mg/kg, IP) and kept at a constant 37°C using a
heating pad for the duration of the recording (60 minutes). ECG
signals were acquired using a DSI Ponemah ampliﬁer and
pClamp Axoscope 10 software (Molecular Devices). P-wave
duration, QRS duration, and QT intervals were determined
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during the ﬁrst 15 minutes after anesthesia. The QT interval
was corrected as a function of the R-R interval (QT-corrected,
QTc ¼ QTﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
RR=100
p ), as done by Mitchell et al.20 AV blocks
(impaired conduction between atria and ventricles) and sinus
atrial (SA) node dysfunction (absence of P waves) were
assessed during the 60 minutes of recording.
Statistical Analysis
NormalityofsampleswasveriﬁedbyShapiro-Wilk test.Unpaired t
tests were used for comparison between 2 groups. Two-way
ANOVA with Tukey post hoc tests were used for comparison
between >2 groups. Data are expressed as meanSEM, and
P<0.05 was considered statistically signiﬁcant.
Results
GC1 Is in Close Proximity to Cx43 at the ID in
Mouse Heart
Immunoﬂuorescence imaging of heart ventricle cryosections
showed both a1 and b1 subunits of GC1 together with Cx43
at the ID (yellow arrowheads, ﬁber longitudinal orientation;
Figure 1A). The potential association to Cx43 is illustrated by
a 3-dimensional reconstitution of Z-stack confocal images
(optical sectioning; Figure 1B). As negative control, we
omitted the primary antibodies (Figure S1A). Weak overlap-
ping signals between Cx43 and GC1 at the ID are also
observed in orthogonal sections of the Z-stack images
(Figure S1B).
GCab and Cx43 Form a Complex in the Mouse
Heart
Ventricle homogenates were prepared by separating cytosol
from membrane fraction or by lysis with 1% Triton X-100
(“total”; Figure 2), as described in Methods. Inputs (starting
material, left panel) showed that cytosol contains a high
level of GCa and GCb and no Cx43, as expected. High levels
of Cx43 are detected in the membrane fraction. GCa1 and
GCb1 are also detected in the membrane fraction, as
previously reported.5 More important, coimmunoprecipitation
(right panel) of Cx43 with anti-GCb1 antibody yields robust
signals in both membrane fraction and total homogenate;
the a1 subunit is coimmunoprecipitated with anti-GCb1 but
to a lesser extent than the b1 subunit. There is no
immunoprecipitation of Cx43 or GC1 when nonspeciﬁc IgG
is used or in the cytosolic fraction. The reverse coimmuno-
precipitation using an antibody against Cx43 (directed
against the C- or N-terminal peptide of Cx43) did not pull
down GC1 in Triton-soluble homogenates or membranes (not
shown). The reason is unknown but could be related to
solubilization, masking of the Cx43 recognition site in the
GC1-Cx43 complex, or an intercalated factor between Cx43
and GCab1.
GJ Permeability Is Impaired in GCa1-KO Mice
To determine whether there is a physiological link between
GC1 and Cx43, we used the systemic GCa1-KO model21 to
assess GJ function. For this, we compared GJ permeability in
the heart of WT and GCa1-KO mice by measuring, in the
ventricle, the diffusion of LY. LY goes through GJ, whereas red
dextran (which does not go through GJ because of its size) is
used to mark the site of injection. Figure 3 showed that the
diffusion of LY is signiﬁcantly impaired in the GCa1-KO mice,




Figure 1. Guanylyl cyclase (GC) a1 and b1 subunits are
localized in proximity to connexin 43 (Cx43) at the intercalated
discs. A, Representative image (n=4) of wild-type (WT) heart
cryosections immunostained for GCa1 and GCb1 (left panels,
red), Cx43 (green, middle panels), and merged signal (right
panels). Cardiomyocyte membranes are stained with wheat germ
agglutinin (WGA; white). Yellow arrowheads indicate intercalated
discs (IDs). White bar=20 lm. Negative controls are shown in
Figure S1. GC1 represents the heterodimer formed by association
of GCa1 and GCb1 subunits (the other GCa subunit, GCa2, was
not included in the present study). B, Representative 3-
dimensional reconstitution of Z-stack images (0.5–0.7 µm slices)
of heart cryosections. GCa1 (top panel) and GCb1 (bottom panel)
are immunostained in red, Cx43 in green, and cardiomyocyte
membranes in white with WGA (n=3). Magniﬁcation of ID area
(boxes, right panels) indicates a close proximity between Cx43
and GCa1 or GCb1.
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Mice Lacking the GCa1 Subunit Have
Mislocalized Cx43, as Do Mice Treated With AngII
Lateralization of Cx43 (eg, accumulation of Cx43 hemichan-
nels at the membranes along the longitudinal axis) is linked to
cardiac diseases related to Cx43-containing GJ dysfunc-
tion.19,22,23 Thus, to further establish a correlation between
GC1-Cx43 association and GJ function, we assessed the
localization of Cx43 in the GCa1-KO model and under AngII-
induced stress conditions. We used a model of AngII-induced
cardiac hypertrophy because we previously showed that in this
model, GC1 is desensitized to NO stimulation (eg, reduced
NO-stimulated activity).15 We assessed localization of Cx43 by
measuring the amount of Cx43 outside the ID in 4 groups: WT,
WT treated with AngII, GCa1-KO, and GCa1-KO treated with
AngII, as described in Methods. We observed that the lack of
GCa1 induces abnormal localization of Cx43, which accumu-
lates primarily at the lateral membrane of the cardiomyocytes
in the ventricle (Figure 4A). Figure 4B showed that this
lateralization is statistically signiﬁcant, as is Cx43 lateraliza-
tion of WT and GCa1-KO mice treated with AngII, compared
with untreated WT mice. Interestingly, the percentage of Cx43
lateralization is not further increased by AngII treatment in
GCa1-KO mice, which could mean that the same Cx43 location
mechanism is disrupted by AngII treatment and deletion of
GCa1 or that 30% lateralization represents a plateau. The
abnormal localization of Cx43 indicates that one or more of the
processes that guide Cx43 trafﬁcking and/or assembly at the
ID are impaired by the lack of GCa1 or AngII treatment.
A Signiﬁcant Decrease in Cx43-Containing GJs at
the ID Is Observed in WT and GCa1-KO Mice
Treated With AngII
Wenext wanted to determine whether the lateralization of Cx43
together with the decreased GC permeability were reﬂected in
the decrease of Cx43-containing GJ speciﬁcally in the junctional
plaques. We conducted fractionation of the heart to isolate the
junctional plaques at the ID from the membrane fraction in the
WT and GCa1-KO mice untreated or treated with AngII. After
separation from the cytosolic fraction, the membrane fraction
was solubilized with Triton X-100. The fraction that is not
Triton-soluble corresponds to the ID and contains the junctional









Figure 2. Guanylyl cyclase, a heme-containing a1b1 heterodimer
(GC1), and connexin 43 (Cx43) coimmunoprecipitate. Representa-
tive Western blot showing pull down of Cx43 by anti-GCb1 (n=3).
Cytosolic (Cyt) and membrane (Mb) fractions and whole heart
homogenate (total) were immunoprecipitated with anti-GCb1 and
probed with anti-GCa1, anti-GCb1, or anti-Cx43. Input indicates the
starting material (30 lg lysates). In the negative control (wild-type
membrane fraction pulled down with IgG), no Cx43 could be
detected. Unlike the subsequent experiments, homogenates were
prepared in the absence of phosphatase inhibitors, which could
explain the lack of phosphorylated forms of Cx43.
































Figure 3. Gap junction permeability is impaired in guanylyl cyclase a1 knockout (GCa1-KO) mice heart. A, Ventricle slices from wild-type (WT)
or GCa1-KO mice hearts were locally injected with Lucifer yellow (LY; gap junction [GJ] permeable) and Red Dextran (RD; GJ not permeable) and
incubated for 15 minutes at 37°C. After ﬁxation, ﬂuorescent areas were measured using Axiovision software on 14-µm cryosections with a 200
Axiovert Zeiss ﬂuorescent microscope (see Methods). Bar=100 lm. B, The difference between areas stained with LY (dye diffusion through GJ)
and with RD (site of injection) indicates that diffusion of LY is impaired in GCa1-KO mice heart compared with WT (GCa1-KO vs WT,
48 9378837 vs 91 6458834 lm2; n=5 for each group). Data are expressed as meanSEM (B). BF indicates bright ﬁeld. **P<0.01.
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expected, the cardiac cytosolic fraction does not have
detectable Cx43 (Figure 5A). GCa1-KO mice, in addition to
lacking the a1 subunit, have decreased levels of the GCb1
subunit. AngII has no effect on the levels of GC (left panel;
Figure 5A). The membrane fraction (minus the junctional
plaques, middle panel) displays a trend of increased Cx43 in
WT mice treated with AngII and in GCa1-KO miceAngII
compared with WT control that was not signiﬁcant between the
4 groups (Figure S2A). Interestingly, there is a signiﬁcant
decrease in the amount of Cx43 at the ID (urea-treated/Triton-
insoluble membrane fraction) in WT and GCa1-KO mice treated
with AngII (Figure 5A, right panel, and Figure 5B). There is also
a trend of decreased detection of Cx43 at the ID in GCa1-KO
compared with WT that did not reach signiﬁcance (Figure 5B;
loading control for each fraction was estimated by Ponceau Red
staining of the blotted membranes; Figure S2B). This decrease
in Cx43-GJ abundance at the ID in WT and GCa1-KO
mice treated with AngII correlates with the increased Cx43
lateralization at the membrane in the same groups of mice.
All together, these results suggest that Cx43-GJ remodeling
takes place in AngII-treated WT and GCa1-KO mice.
Cx43-GC1 Association in the Heart Is Disrupted
by AngII Treatment
We next wanted to assess, by coimmunoprecipitation (as in
Figure 2), whether the increased Cx43 mislocalization
correlated with a disruption of the Cx43-GC1 association.
The left panel of Figure 6A (input, starting material) showed
that there is no decrease of Cx43 or GC1 in the membrane
fraction of heart treated with AngII and, as expected, no
GCa1 is detected in the input of the GCa1-KO mice. On
the other hand, the middle panel (coimmunoprecipitation)
indicated that the amount of Cx43 pulled down by anti-
GCb1 is signiﬁcantly decreased in the heart of AngII-treated
mice compared with control (WT untreated), whereas the
level of GCb1 (and GCa1) pulled down by anti-GCb1 is not
reduced by AngII treatment. The increased amount of
unbound Cx43 (eg, not pulled down by anti-GCb1) in the
AngII-treated mouse hearts conﬁrms the decreased coim-
munoprecipitation in these groups. Likewise, Cx43 is
detected in the unbound material of GCa1-KO and IgG
(right panel; Figure 6A). Statistical analysis in Figure 6B
indicated that the decreased pull down of Cx43 is
signiﬁcant for WT and GCa1-KO treated with AngII
compared with untreated WT and for GCa1-KO treated
with AngII versus untreated GCa1-KO (Figure 6B). Interest-
ingly, there is no signiﬁcant difference in the pull down of
Cx43 between WT and GCa1-KO. This could suggest that the
association between GC1 and Cx43 primarily involved the b
subunit of GC1. Together, these results indicate that the Cx43-
GC1 association in the heart is disrupted by AngII treatment
and is not attributable to a decreased expression of Cx43 (or
GCb1).
WT + AngII GCα1 KO + AngII
























Figure 4. Connexin 43 (Cx43) lateralization is increased by angiotensin II (AngII) treatment
and in guanylyl cyclase a1 knockout (GCa1-KO) mice. A, Representative images of Cx43
localization in heart cryosections from wild-type (WT) and GCa1-KO mice untreated or
treated with AngII. Cx43 is immunostained in red, and N-cadherin is immunostained in green.
Nuclei (blue) and membranes (white) are stained with 40,6-diamidino-2-phenylindole and
wheat germ agglutinin, respectively. N-cadherin is speciﬁc to intercalated discs (IDs; white
arrows). Some of Cx43 labeling outside the ID is indicated by yellow arrowheads. White
bar=10 lm. B, Statistical analysis of the percentage of Cx43 signal detected outside the ID
(determined by nonoverlapping signals of Cx43 and N-cadherin), as described in Methods.
Compared with WT mice (7.61.4% of Cx43 outside the ID), there is a signiﬁcant increase in
lateralization of Cx43 in WT and GCa1-KO mice treated with AngII (WT+AngII, 24.01.8%;
and GCa1-KO+AngII, 30.44.4%) and in untreated GCa1-KO mice (GCa1-KO, 18.01.2%).
n=4 for each group. Data are expressed as meanSEM (B). *P<0.05, **P<0.01.
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A Signiﬁcant Decrease in Serine 365
Phosphorylation in Cx43-Containing GJs at the ID
Is Observed in WT and GCa1-KO Mice Treated
With AngII
Cx43 trafﬁcking, channel assembly, and gating, which are
highly dynamic, are modulated by protein kinases: each
speciﬁc step of the Cx43-GJ life cycle corresponds to
phosphorylation of speciﬁc residues by speciﬁc kinases,
including PKA.11,25 Although phosphorylation by protein
kinase G (activated by cGMP) remains controversial, cGMP is
known to modulate cAMP-hydrolysis by phosphodiesterases in
cardiomyocytes. As such, we investigated whether the Cx43
mislocalization seen in our different models was because of
alteration of cAMP-PKA–dependent phosphorylation of Cx43.
We focused on phosphorylation at serine 365 of Cx43 because
PKA activity enhances Cx43 trafﬁcking to the PM and
assembly of Cx43-containing GJs through increased phospho-
rylation at this residue.26,27 Using an antibody speciﬁc for
phosphoserine 365 of Cx43, we measured the phosphoryla-
tion signal in the ID fraction from WT and GCa1-KO mice
untreated or treated with AngII (Figure 7A). As shown in
Figure 7B, phosphoserine 365 detection levels are signiﬁ-
cantly decreased in both WT and GCa1-KO mice treated with
AngII, compared with the WT control group.
Abnormal Electrical Propagation in GCa1-KO Mice
Treated With AngII
We performed ECGs in WT and GCa1-KO mice treated or not
with AngII to evaluate electrical function. We observed abnor-
mal ventricular electrical propagation in GCa1-KO mice+AngII,
which is signiﬁcant compared with WT, WT+AngII, or GCa1-KO
mice (Figure 8). In particular, recording traces of WTAngII and
GCa1-KOAngII (Figure 8A) showed that GCa1-KO mice
treated with AngII display a signiﬁcant prolonged QRS duration
and QTc interval (Figure 8B-C), which indicate a slower
electrical propagation and delayed repolarization in the ventri-
cles, respectively. The abnormal ventricular electrical propaga-
tion is consistent with the GJ decreased abundance and Cx43
lateralization. We also observed supraventricular electrical
disturbance (Figure S3), which is further discussed later.
Discussion
Cx43 has long been recognized as a critical player in cardiac
function. Cx43 forms GJs located at the ID that are
responsible for electrical propagation in the ventricular
myocardium. In mice, cardiac-speciﬁc KO of Cx43 leads to
ventricular arrhythmia and sudden cardiac death in the ﬁrst
2 months.29 On the other hand, NO signaling is also an
important modulator of cardiac function. NO stimulates GC1
to produce cGMP, which negatively regulates cardiomyocyte
contractility by modulation of calcium homeostasis via protein
kinase G–dependent phosphorylation.14,30
Cx43-GC1 Association
To our knowledge, a direct link between Cx43 function and
NO signaling has not been reported in cardiomyocytes. There
is one report in mesangial cells, showing that stimulation of
the NO-cGMP pathway increases Cx43-containing GJs and
enhances GJ function.31 Our ﬁndings that Cx43 and the NO
receptor (eg, GC1) are associated in the heart is novel and is
based on biochemical evidence showing that GC1 and Cx43
coprecipitate in the membrane fraction of the heart and on
































































Figure 5. Connexin 43 (Cx43) levels are signiﬁcantly decreased in the intercalated disc (ID) fraction of angiotensin II (AngII)–treated wild-type
(WT) and guanylyl cyclase a1 knockout (GCa1-KO) mice. A, Representative Western blot of GCa1, GCb1, and Cx43 from cytosol, Triton-soluble
membrane, and Triton-insoluble fractions (junctional plaques/IDs) from WT and GCa1-KO mouse heartsAngII (10–50 lg of proteins loaded).
We did not expect to detect GC1 at the junctional plaques because the treatment with Triton X-100 and urea probably removes/degrades it. B,
Densitometry analysis of Cx43 level in the ID fraction. A decreased Cx43 level at the ID was signiﬁcant in AngII-treated WT (WT+AngII) and
GCa1-KO (GCa1-KO+AngII) mice compared with untreated WT (WT and WT+AngII, n=5; GCa1-KO and GCa1-KO+AngII, n=4). Data are expressed
as meanSEM (B). Ctrl indicates control (untreated). *P<0.05, ***P<0.001.
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Although not in adult cardiac tissues, a proximity ligation
assay in neonatal cardiomyocytes also indicates an interac-
tion between endogenous Cx43 and GC1 (Figure S4). Because
the neonatal cardiomyocytes are not adult cardiomyocytes, it
is difﬁcult to conclude whether the few complexes detected
at the junction between 2 neonatal cardiomyocytes
represent GJ.
Impaired GJ Function in Mice With an Altered NO-
GC-cGMP Pathway
After these initial observations, our ﬁrst aim was to investi-
gate the function of this association and the impact of a
decreased functional NO-cGMP pathway on Cx43 location and
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Figure 6. The guanylyl cyclase, a heme-containing ab heterodimer (GC1)-connexin 43 (Cx43) complex is disrupted in the cardiac membrane
fraction of wild-type (WT) and GCa1 knockout (GCa1-KO)mouse hearts treated with angiotensin II (AngII). A, Western blot of GCa1, GCb1, and Cx43
showing coimmunoprecipitation of Cx43 by anti-GCb1 in the cardiac membrane fraction and decreased pull down of Cx43 by anti-GCb1 in AngII-
treated mice. Left panel indicates the starting material (input) for GCa1, GCb1, Cx43, and b-actin in heart membranes fromWT and GCa1-KO mice
untreated (control [Ctrl]) or treated with AngII. The different bands of Cx43 include unphosphorylated and phosphorylated forms of Cx43.24 b-Actin
is loading control. As expected, no GCa1 is detected in lysates of the GCa1-KO hearts, whereas Cx43 levels were slightly reduced (input, left panel).
Coimmunoprecipitation (middle panel) was done on the membrane fraction with anti-GCb1 or rabbit IgG as negative control. AngII treatment
decreases pull down of Cx43 in bothWT and GCa1-KOmice. Unbound fraction (right panel) contains the Cx43 not pulled down by anti-GCb1 or IgG.
B, Densitometry analysis of Cx43 pull down. Results are expressed as the ratio of coimmunoprecipitation of Cx43/input Cx43/immunoprecipitation
of GCb1 (fold WT control). There is a signiﬁcant decrease of Cx43 coimmunoprecipitation in AngII-treated vs untreated WT mice, in AngII-treated vs
untreatedGCa1-KOmice, and in AngII-treatedGCa1-KOmice comparedwith untreatedWTmice. n=7 for eachWT andWT+AngII group. n=4 for each





































Figure 7. Treatment with angiotensin II (AngII) decreases serine 365 phosphorylation of
connexin 43 (Cx43) in junctional plaques of heart from wild-type (WT) and guanylyl cyclase
a1 knockout (GCa1-KO) mice. A, Representative Western blot of intercalated disc (ID)
fraction from WT and GCa1-KO mice untreated (control [Ctrl]) or treated with AngII and
probed for “total” Cx43 (using Cx43 N-terminal antibody) and Cx43 phosphorylation
speciﬁc for serine 365 antibodies. B, Densitometry analysis of the ratio of phosphoserine
365–Cx43 signal/total Cx43 and expressed as fold WT control indicates a signiﬁcant
decrease in WT and GCa1-KO mice treated with AngII compared with WT control. n=3 for
each group. Data are expressed as meanSEM (B). *P<0.05, **P<0.01.
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systemic knockout of the GCa1 subunit.18 Functionally, we
observed that GJ permeability assayed by dye spread in
ventricle slices is signiﬁcantly reduced in the heart of mice
lacking the GCa1 subunit, supporting a link between GC1 and
Cx43 (Figure 3). This supports the novel idea that a decrease
in the NO-cGMP pathway affects GJ function in the heart and
speciﬁcally in the ventricle.
Altered NO-GC-cGMP Pathway Correlates With
Mislocalization of Cx43
We next asked whether this decreased function was
attributable to a decrease in Cx43-containing GJ at the ID.
In addition to the GCa1-KO mice model, we used an AngII-
induced hypertrophy mouse model for 2 reasons. First, we
previously showed that AngII treatment desensitizes GC1
activity to NO stimulation in the vasculature15 and in the heart
(Figure S5), giving us another model of the impaired NO-GC-
cGMP pathway. Second, we wanted to assess whether stress-
induced disruption of the GC1-Cx43 association could have a
pathological relevance. The AngII treatment and the lack of
GCa in GCa1-KO mice induce a signiﬁcant increase of Cx43
outside the ID and apparent Cx43 accumulation in the lateral
membranes along the longitudinal axis of the ventricular
cardiomyocytes. This is an important observation because it is
proposed that activity of these unapposed hemichannels at
the lateral membrane results in a “leaky” current that could
lead to abnormal electrical propagation.32,33 The increased
lateralization of Cx43 in AngII-treated GCa1-KO is similar in
untreated GCa1-KO and in AngII-treated WT (no additive
effect), which could suggest that the GCa1-KO and AngII
treatment disrupts the same pathway involved in Cx43
localization or that the 30% lateralization corresponds to a
plateau of Cx43 mislocalization under our conditions (13-day
AngII treatment or partial KO of GC activity). We favor the
latter explanation because it is consistent with the results of
our fractionation experiment, as follows. The abnormal
localization of Cx43 is also detectable through a reduction
of Cx43 within GJs at the ID in the ventricles of AngII-treated
WT mice, and this depletion is signiﬁcantly exacerbated in
GCa1-KO mice when treated with AngII. This would suggest























































Figure 8. Abnormal electrical propagation in the ventricle of guanylyl cyclase a1 knockout (GCa1-KO) mouse. A, Representative ECG traces
recorded from wild-type (WT) mice untreated (control [Ctrl]; n=6) or treated with angiotensin II (WT+AngII; n=7) in left panels and from GCa1-KO
mice untreated (Ctrl; n=6) or treated with AngII (GCa1-KO+AngII; n=6) in right panels. B, ECG trace showing scales and parameters used in the
analysis (P-wave duration, QRS duration, and QT-corrected [QTc] interval). QRS duration was deﬁned as in the study by Li et al28 and evaluates
progression of depolarization. An isoelectrical level was used to determine the beginning of the T wave. C, Left panel: QRS duration of GCa1-KO
mice treated with AngII (GCa1-KO+AngII; n=6) is signiﬁcantly increased, indicating a slower electrical propagation, compared with WT (n=6) or
AngII-treated (n=7) and GCa1-KO control mice (n=6). Right panel: QTc interval in GCa1-KO mice treated with AngII (n=7) is also increased
compared with WT (n=6) and GCa1-KO mice control (n=6), but not different from WT treated with AngII (n=6). QTc=QT/√(RR/100). n=6 to 7
for each group. Data are expressed as meanSEM (C). *P<0.05, **P<0.01, ***P<0.001.
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AngII have an additive effect on Cx43 mislocalization. We
could not detect GC1 in the ID fraction, but this is not
surprising because the isolation of junctional plaques from the
Triton-insoluble fraction with 4 mol/L urea would be expected
to “damage” GC1.
The signiﬁcant increase in Cx43 lateralization in GCa1-KO
compared with WT mice is consistent with the decreased,
albeit nonsigniﬁcant, level of Cx43 present at the ID. The
signiﬁcant versus nonsigniﬁcant discrepancy could be
because of differences in sensitivity of the 2 methods
(immunoﬂuorescent pixel analysis via ImageJ versus densit-
ometry analysis of anti-Cx43 blots after fractionation) or
because the immunoﬂuorescence signal for lateralized Cx43
is the sum of the Cx43 attributable to the disassembly of GJ
plus Cx43 that is trafﬁcked from the Golgi to the PM before
the assembly of any GJ.9,34 Independently of the potential
mechanism, the correlation between decreased GJ perme-
ability and increased percentage of Cx43 outside the ID in
GCa1-KO mice strongly supports a link between GJ function
and the NO-cGMP pathway.
Potential Molecular Mechanism
Cyclic nucleotide signaling is highly compartmentalized, mostly
through the activity of phosphodiesterases,12 and proper
cardiac physiological function relies on the organization, in
microdomains, of these intracellular signaling pathways.13,14
Disruption of the cAMP-related signaling could be induced, for
example, by dysregulation of the cGMP-inhibited phosphodi-
esterase 3, which preferentially hydrolyzes cAMP.13,35 As such,
disruption of the NO-cGMP pathway would impair PKA
activation through increased cAMP hydrolysis by phosphodi-
esterase 3. PKA activity enhances Cx43 trafﬁcking to the PM
and maintenance of Cx43-containing GJs, through increased
phosphorylation at serine 364/365.26,27 This led to our
mechanistic hypothesis that Cx43 mislocalization could be
because of alteration of PKA-dependent upregulation of serine
364/365 phosphorylation of Cx43 in the GC1 activity-impaired
mouse models. We observed a decrease in Cx43 phosphory-
lation at serine 365 in the junctional plaques (ID, Triton-
insoluble fraction) of WT treated with AngII and GCa1-KO
miceAngII (Figure 7A). This decrease was signiﬁcant in WT
and GCa1-KO mice treated with AngII (not in GCa1), compared
with untreated WT (Figure 7B). To our knowledge, this is the
ﬁrst evidence that AngII treatment of WT and GCa1-KO mice
induces a change in phosphoserine 365 of Cx43. The
nonsigniﬁcant decrease in phosphoserine 365 in GCa1-KO
suggests that phosphorylation of another residue(s) involved in
Cx43 trafﬁcking could be under the control of the NO-GC1
pathway. Overall, our biochemical data indicate that there is a
strong correlation between the decreased serine 365 phos-
phorylation, the decreased GJ abundance, and increased Cx43
lateralization on treatment with AngII of WT and that Cx43
mislocalization is exacerbated if the AngII treatment is applied
to mice lacking the GCa1 subunit. This suggests that the AngII
treatment and the lack of GCa1 could affect Cx43 trafﬁcking
and assembly at 2 different steps (such as differential Cx43
phosphorylation). Further study will be conducted to investi-
gate the involvement of phosphodiesterase 3, PKA, and an
unbalanced cAMP/cGMP pool at the ID in NO-cGMP–
dependent Cx43 trafﬁcking. We cannot rule out that other
pathways of Cx43 trafﬁcking and GJ life cycle, besides
phosphorylation, are affected, including microtubule-depen-
dent forward trafﬁcking to the junctional plaques.36
Abnormal Electrical Propagation in AngII-Treated
GCa1-KO Mice
We investigated further the functional implications of
decreased NO-cGMP signaling by recording an ECG in WT
and GCa1-KO mice with and without AngII treatment, because
Cx43 lateralization and GJ abundance reduction should
translate into cardiac electrical dysfunction37 in the AngII-
treated GCa1-KO mouse model. Our biochemical data,
obtained from the ventricle of GCa1-KO mice treated with
AngII, showing decreased GJ abundance and Cx43 lateraliza-
tion, may explain the abnormal ECG in these mouse models.
In particular, the prolonged QRS duration and longer QTc
interval are indicative of a slower ventricular electrical
propagation and repolarization, respectively. The longest
QRS duration and largest QTc interval were observed in the
AngII-treated GCa1-KO model, which was the model in which
the most signiﬁcant decrease of Cx43 at the ID and the
largest Cx43 lateralization were observed, suggesting a strong
correlation between the electrical dysfunction and the Cx43
mislocalization. However, the disruption of the Cx43 and GC1
association at the ID could indirectly affect other key players
of electrical conduction, notably sodium channels whose
dysfunction also accounts for ventricular arrhythmias.38
Moreover, sodium channels are associated with the ID,39
and Cx43 KO is associated with decreased Nav1.5.40 Thus, we
analyzed the potential effect of sodium current in ventricular
cardiomyocytes isolated from WT and AngII-treated GCa1-KO
mice by patch-clamp recording of their action potentials
(Figure S6). We observed that action potential amplitude
remained the same in AngII-treated GCa1-KO myocytes
compared with WT myocytes. Furthermore, no difference
was observed in the maximal change rate in membrane
potential phase 0, which is the steepest portion of the action
potential upstroke representing the maximal sodium ion ﬂow
(ie, sodium channel conductance).41,42 These results suggest
that the conduction disturbance in GCa1-KO mice treated
with AngII is most likely not mediated by the sodium current.
Action potential duration (Figure S6) was prolonged in AngII-
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treated GCa1-KO mice compared with WT, which is consistent
with the prolonged QTc interval found in the ECG recording of
Figure 8. We also observed the occurrence of early afterde-
polarizations in some cardiac cells isolated from the AngII-
treated GCa1-KO mice (top right panel of Figure S6). These
results suggest that AngII-treated GCa1-KO mouse hearts
exhibit both substrate and trigger that could favor cardiac
arrhythmogenesis.
Interestingly, we also observed abnormal supraventricular
(SA node and atrium) electrical propagation (Figure S3).
Although the mechanisms are still poorly understood, several
lines of evidence suggest that disruption of the NO-cGMP
pathway affects supraventricular function. For example, it is
proposed that the NO-cGMP pathway modulates the L-type
calcium current in atrial myocytes43,44 and the hyperpolar-
ization-activated current in the SA node.45–47 Thus, the
observed absence of P waves and AV block could be
explained by SA dysfunction in the GCa1-KO, independently
of its association with Cx43. The signiﬁcant prolonged
duration of P waves in GCa1-KO mice treated with AngII is
consistent with a slower electrical conduction in the atrium.
Although Cx43 expression in the SA node is limited,
suggesting that the Cx43-GC1 association might not be at
work in the observed SA node dysfunction, atrial GJs are
formed of both Cx40 and Cx43,48 and we detected GC1 in the
atriums (Figure S7, which, to our knowledge, has not been
previously reported). As such, we cannot exclude that the
supraventricular dysfunction could be linked partially to a
disrupted Cx43-GC1 association in the atrium. Whether this is
one of the underlying mechanisms of abnormal supraventric-
ular propagation will require further investigation.
Potential Function of the Cx43-GC1 Association
A link between AngII-induced hypertrophy/remodeling, Cx43
dysfunction, and arrhythmogenicity has been proposed, but the
molecularmechanism remains largely unknown.16,49 In humans
and animals subjected to a prolonged state of cardiac
hypertrophy, the initial compensatory mechanisms and their
failure lead to maladaptive structural remodeling associated
with decreased Cx43 assembly in GJs at the ID and increased
Cx43 membrane lateralization.19,22,23,50 Mouse models of
pressure overload–induced hypertrophy/remodeling showed
that protein kinase G and GC1 activity is downregulated and
that the localization of GCb1 is directly disrupted.6,51 We
observed signiﬁcant hypertrophy compared with WT in all
studied groups (Figure S8), but no other obvious structural
damage was seen (not shown). Conversely, cGMP is a negative
regulator of the cardiac hypertrophy–related remodeling pro-
cess,52 and it was recently shown that stimulation of GC1
activity protects from pathological remodeling and heart failure
after myocardial infarction.53 With our observation that Cx43
mislocalization correlates with decreased biochemical detec-
tion of the Cx43-GC1 association in WT and GCa1-KO treated
with AngII, this leads us to propose that the NO-cGMP pathway
protects against hypertrophy-induced remodeling and Cx43-GJ
dysfunction via a functional Cx43-GC1 association, potentially
at the ID. However, because the GCa1-KO is systemic (as is
AngII treatment), we cannot rule out that some effects are
attributable to GC1 activity impairment in other tissues,
particularly the vascular system. Future work using an inducible
cardiomyocyte-speciﬁc GC1 KO model will provide more
speciﬁc information. Yet, this study clearly establishes that an
intact NO-GC-cGMP pathway is critical, directly or indirectly, for
Cx43 proper location and function under oxidative stress.
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A: Negative control for 
immunofluorescence. Representative 
image of immunofluorescence of heart 
cryosection from WT mice performed with 
secondary AlexaFluor488 goat anti-mouse 
and AlexaFluor594 goat anti-rabbit (1:200) 
and without primary antibodies with same 
exposure time as in Figure 1. No red or 
green signal is detected. Nuclei and 
membranes are stained in blue with DAPI 
and in white with Wheat Germ Agglutinin 
(WGA), respectively. (n=4)
B: Overlapping of GC and Cx43 signals. The yellow signals (black arrows) detected 
in ID of the right orthogonal section (blue box) and the top orthogonal section (red 
box)  of the optical sectioning indicate an overlap of immunolabeled GCβ1 (red) and 
Cx43 (green). This picture is representative of n=3. There is a low signal overlap 
between the Cx43 and GC under these conditions, reminiscent of the moderate co-
localization observed between ZO-1 and Cx43 at the ID (Barker, RJ et al. , Circulation 
Research 2002; 90:317-334).
Figure S1.














































Probing of Cx43 and total protein in cytosolic, membranes (triton soluble) and 
junctional plaques (triton insoluble) fractions of WT and GCα1 KO mice ± AngII. 
A- Densitometry analysis of Cx43 level in the membrane fraction (triton soluble). There was
no significant change compare to WT control (P>0.05, n=4)
B- Representative image of nitrocellulose membranes probed with anti-Connexin 43 or
stained with Ponceau red after transfer of 10-50 µg of proteins from WT Ctrl, WT+AngII,

















































































Supraventricular abnormality in electrical propagation in GCα1KO mice heart. 
(A) Representative traces recorded from WT (n=6) and GCα1 KO mice (n=6) show that GCα1 KO mice have
(a) irregular RR interval (dotted double arrows) and atrioventricular (AV) block (3rd degree, * indicates
uncoupled P-waves); (b) absence of P-waves, which are indicative of dysfunction in sinoatrial (SAN)
conduction.
(B) The incidence of AV block and SA node impairment was significantly higher in GCα1 KO mice compared to
WT (6 GCα1-KO mice out of 10 and 0 WT mice out of 6; * P<0.05, Fisher exact test). The duration of AV
blocks or SAN dysfunction was analyzed in a 10-minute recording period and the supraventricular
abnormalities were observed for 4.4 ± 0.9 min.
(C) Significant prolonged duration of P-wave in GCα1 KO treated with AngII (n=6), compared to WT (n=6), WT
+ AngII (n=6) and untreated GCα1 KO (n=7), which reflects a slower electrical conduction in the atrium. **:
P<0.01 and ***: P<0.001. Data are expressed as mean±S.E.M.








Cx43 alone A GC1–Cx43 complex is detected in rat
neonatal cardiomyocytes (NCM) by proximity 
ligation assay. Representative fluorescent 
image (n=3, independent cultures) of GCα1-
Cx43 (top left) and GCβ1-Cx43 association (top 
right) detected by proximity ligation assay (PLA). 
Red dots indicate endogenous complex. Black 
arrows indicate GC-Cx43 complex potentially 
located at the junction between two NCM. As a 
negative control, cells were incubated with anti-
Cx43 only (no anti-GC antibodies, bottom left). 
White bar scale: 20 µm. Images were taken with 
200 Axiovert Zeiss fluorescent microscope 
equipped with ApoTome (confocal-like system) 
at 63X magnification and with DIC.



































NO-stimulated GC activity is significantly decreased in cardiac 
membrane fraction by AngII treatment. cGMP production after 
stimulation with 100 µM S-Nitroso-N-acetyl-D-penicillamine (SNAP, Nitric 
Oxide donor)  of 10-50 µg protein for 10 minutes at 37°C was determined 
by Enzyme Immuno Assay in cytosolic and membrane fractions of hearts 
from control (Ctrl, n=3) or AngII-treated (n=3) mice. GC activity is 
significantly decreased in heart membrane fraction of mice treated with 
AngII (*, P<0.05). The decreased trend in cytosol was strong but not 
significant. 







Action potentials (AP) recorded from ventricular myocytes isolated from WT and AngII-treated GCα1KO
mice. (A) Representative traces and dV/dt values recorded from a ventricular myocyte in each group as indicated.
Note the occurrence of early afterdepolarizations (EADs) in three APs shown in different colors (upper right panel).
(B) Summarized data for maximal dV/dt of AP upstroke. (C) Summarized data for action potential amplitude (APA).
(D) Summarized data for AP duration at 50% repolarization (APD50). The number of cells is indicated above each bar.
Methods
Cell Isolation: Ventricular myocytes were enzymatically isolated from the left ventricles of adult mouse hearts. After being
anesthetized with isofluorane, the hearts were removed and perfused retrogradely in Langendorff fashion at 37C with
nominally Ca2+-free Tyrode’s solution containing ~1mg/ml collagenase (type II; Worthington) and 0.1mg/ml protease (type
XIV, Sigma) for 11-13 minutes. After washing out the enzyme solution, the heart was removed from the perfusion apparatus
and swirled in a culture dish. The Ca2+ concentration was slowly increased to 1.0mM and the cells were stored at room
temperature until they were ready for use. The cells were used within 8 hours of isolation. All single cell electrophysiological
experiments were performed at ~35°C.
Patch-Clamp Methods: The myocytes were patch-clamped using the amphotericin B (300 μg/ml) perforated whole-cell
configuration of the patch-clamp technique in the current-clamp mode. To record APs, patch pipettes, (2-5M) were filled
with an internal solution containing (in mM) 110 K+-aspartate, 30 KCl, 5 NaCl, 10 HEPES, 5 EGTA, 0.779 CaCl2 (free Ca200 µM), 5 Mg-ATP, and 5 Na2-creatine phosphate (pH 7.2, adjusted with KOH). The myocytes were superfused withnormal Tyrode’s solution containing (in mM) 136 NaCl, 5.4 KCl, 0.33 Na2PO4, 1.0 CaCl2, 1 MgCl2, 10 glucose, and 10HEPES (pH 7.4). Action potentials (APs) were elicited with 2-ms, 2-4 nA square pulses at a pacing cycle length of 1 sec.






GC1 and Cx43 are expressed in mice atrium. Representative images of immunostaining of GC, N-Cadherin, Cx43 and 
Cx40 in atrium cryosection from WT mice (n=3). GCα1 (red, top panel) and GCβ1 (red, Middle panel) are localized at the 
ID (white arrow) identified with anti N-Cadherin (green). GC is also found around the nucleus and is highly expressed in 
vascular smooth muscle cells of vessels (white arrowhead, middle panel). Cx43 (red) and Cx40 (green) are both 
expressed in mice atrium and show similar location at the membrane (bottom panel). Negative control (bottom right 
image) was processed with secondary antibodies (IIary Ab, AlexaFluor488 goat anti-mouse and AlexaFluor594 goat anti-
rabbit at 1:200) and no primary antibody. Nuclei and membranes are stained in blue with DAPI and in white with WGA, 
respectively. White bar scales: 20 μm –20X objective. Immunofluorescence signals are merged on Differential Interface 
Contrast (DIC) images of the atrium.
Figure S7.
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WT 12.3 +/‐ 0.3
WT + AngII 17.1 +/‐ 0.5
GCα1 KO 16.3 +/‐ 0.8
GCα1KO + AngII 19.5 +/‐ 0.8
A B
GCα1 KO mice develop cardiac hypertrophy that is exacerbated after AngII treatment. 
A) Ratio of heart weight (HW, mg) over tibia length (TL, cm) in AngII-treated WT mice, and GCα1 KO mice ±
AngII indicates significant cardiac hypertrophy compared to WT control (n=5-10).  B) The width of > 8 CM
(longitudinal view) per field of heart cryosections was measured and averaged showing significant enlargement in
WT treated with AngII, and in GCα1 KO mice ± AngII compared to  control WT (n=5-7). *, P<0.05; **, P<0.01; ***,
P< 0.001. Ratio and width values are indicated as mean ± SEM in the tables below.
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